We scan new podcasts and send you the top 5 insights daily.
Nicole DeVinagracia cites M3MI data showing 70% of patients who noticed doctor's office advertising filled a prescription or took medication as prescribed, versus 55% who did not notice ads. That performance gap helps explain why point-of-care spending surpassed $1.2 billion in 2025, according to POCMA's reported industry figure.
Healthcare professionals are oversaturated with information and no longer have time for traditional pharma marketing tactics. This signals a critical need for marketers to develop more concise, valuable, and less intrusive channels to communicate with physicians effectively.
Pharmaceutical advertising is the second leading source of health information for patients. AI can “de-criminalize” it by moving from untrackable broadcast ads to programmatic, personalized, and compliant digital content, turning it into a valuable and trusted patient resource monitored by the government.
While digital advertising constitutes 75% of spend in the general economy, it's only about half that in healthcare. This lag, driven by an entrenched reliance on in-person sales reps, creates a long-term secular tailwind for platforms like Doximity as the industry inevitably shifts its marketing budget online.
By analyzing real-world data with machine learning, Walgreens can identify patients at risk of non-adherence before a clinical issue arises. This allows for early, personalized interventions, moving beyond simply reacting to missed doses or therapy drop-offs.
Pharmaceutical companies invest in creating high-quality, patient-centric educational documents. However, these resources often fail to reach patients because physicians are hesitant to distribute materials bearing a corporate logo, creating a "last-mile" delivery problem for crucial information.
Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.
Primary care physicians often learn about new consumer-focused drugs from repeated patient requests, not from pharma reps. A transparent, cash-pay option removes the friction of prior authorizations, making doctors more willing to prescribe a new medication they've just learned about from their patients.
Nicole DeVinagracia says marketers should stop expecting every tactic to perform the same job. She positions TV as a reach vehicle and point-of-care as the channel that turns awareness into education and more informed conversations with healthcare providers. That differentiation should shape how channels are incorporated into media plans.
An executive order mandated lengthy risk disclosures in pharmaceutical TV ads, reducing their effectiveness and ROI. This regulatory change made traditional consumer advertising less attractive, accelerating the shift of billions in pharma marketing spend toward more efficient digital channels like Doximity.
Beyond simple advertising, a new system is developing where patients can initiate treatment, get a digital prescription via telehealth, and use non-traditional channels to get medicine. This model thrives in areas where insurance creates friction and a cash price is viable.